), have previously been implicated in the regulation of important PMN functions, including selectin-mediated trafficking across vascular endothelium. Although glycans, such as Le x and sLe x , which are based on the type 2 sequence (Galb1-4GlcNAc-R), are abundant on PMNs, the presence of type 1 Galb1-3GlcNAc-R glycans required for PMN expression of the closely related stereoisomer of Le x , termed Lewis-A (Le a ), has not, to our knowledge, been reported. Here, we show that Le a is abundantly expressed by human PMNs and functionally regulates PMN migration. Using mAbs whose precise epitopes were determined using glycan array technology, Le a function was probed using Le a -selective mAbs and lectins, revealing increased PMN transmigration across model intestinal epithelia, which was independent of epithelial-expressed Le a . Analyses of glycan synthetic machinery in PMNs revealed expression of b1-3 galactosyltransferase and a1-4 fucosyltransferase, which are required for Le a synthesis. Specificity of functional effects observed after ligation of Le a was confirmed by failure of anti-Le a mAbs to enhance migration using
PMNs from individuals deficient in a1-4 fucosylation. These results demonstrate that Le a is expressed on
Introduction
PMNs are critical, innate immune cells, which are essential for successful elimination of invading pathogens. PMNs also have an important role in wound healing and restitution of mucosal homeostasis at later stages of the inflammatory response. However, dysregulated or excessive PMN influx can result in bystander tissue damage, which is pathognomonic of numerous mucosal inflammatory disorders. During inflammation/ infection, circulating PMNs exit the microcirculation through a sequential extravasation cascade that encompasses PMN capture, rolling, activation, adhesion, and intraluminal crawling [1] . It is well documented that some ligand-receptor recognition interactions during PMN extravasation are controlled by posttranslational glycosylation modifications. For example, glycans on P-selectin glycoprotein ligand 1 have a key role in regulating PMN rolling on the vascular endothelium during inflammatory responses in vivo. The glycans of P-selectin glycoprotein ligand 1 have been extensively studied, and several key glycan modifications (including a1,3 fucosylation, a2,3 sialylation, and b1,4 galactosylation) have been identified as being important for mediating PMN capture and endothelial rolling [2] . In addition, endothelial P-selectin and E-selectin contain binding sites for PMN fucose, containing Lewis family glycans, including sLe Following extravasation, PMNs must migrate through the interstitium and basement membranes before crossing epithelial barriers that line organs such as the lungs and intestine. Although the role of glycan-binding interactions in mediating key steps in PMN transendothelial migration is well accepted, much less is known about the role of glycans once PMNs have exited the microcirculation to undergo the process of migration into epithelial-lined organs. We recently showed that targeting glycans terminating in sLe a [Neu5Aca2-3Galb1-3(Fuca1-4)GlcNAcb-R] on the apical, epithelial glycoprotein CD44v6 prevents shedding of the CD44v6 extracellular domain and results in PMN accumulation on the apical (luminal) epithelial surface [4, 5] . Similarly, targeting of the related Lewis family member Le x , which is selectively expressed on PMN but not epithelial cells, also inhibits PMN TEM [6] .
Despite the importance of Lewis glycans in facilitating both PMN transendothelial migration and PMN trafficking across mucosal epithelium, several Lewis glycans, including Le a have yet to be examined in the context of PMN trafficking. Le a is a blood group Ag glycan, which is usually attached at the nonreducing ends of glycoconjugates and has a role both in cell-cell communication and cell adhesion [7] [8] [9] [10] [11] 
MATERIALS AND METHODS

Antibodies and reagents
Cell culture and PMN isolation
Cultures of T84 and Caco2 IECs (passages 63-68) were grown, as previously described [5, 14] . HL60 cells were obtained from the ATCC (Rockville, MD, USA) and were passaged in RPMI-1640 medium containing 20% heatinactivated FBS (Atlanta Biologicals, Flowery Branch, GA, USA) with supplements and differentiated with DMSO, as described previously [15] . PMNs were isolated from whole blood obtained from healthy human volunteers, with approval from the Emory University and University of Michigan institutional review boards on human subjects, using a previously described density-gradient centrifugation technique [4] . Briefly, whole blood was layered onto Polymorphprep (Alere Technologies) at a ratio of 1:1 and centrifuged at 500 g for 50 min. The PMN-containing layer was carefully collected, and any contaminating erythrocytes were removed by lysis with icecold, sterile water. PMNs were then resuspended in HBSS with 10 mM HEPES, pH 7. Immunoblotting and protein purification PMN cell lysates for immunoblotting were prepared with the following lysis buffer (20 mM Tris, pH 7.5; 150 mM NaCl; 1 mM EDTA; 1% TX-100; 1 mM Na 3 VO 4 ; and 1 mM PMSF) supplemented with 10% mammalian tissue protease inhibitor cocktail (Sigma-Aldrich). PMN cell lysates were boiled in SDS-PAGE sample buffer under reducing conditions, and then subjected to SDS-PAGE followed by transfer to PVDF under standard conditions. Membranes were blocked with 4% milk powder or 3% BSA and incubated with 1 mg/ml of indicated mAb. Primary Ab binding was detected using appropriate HRP-linked secondary Abs (Jackson ImmunoResearch Laboratories, West Grove, PA, USA). N-glycans were removed from PMN protein lysate PNGaseF, according to manufacturer's instructions. Immunoblots are representative of PMNs isolated from 5 independent donors. Functionally active, human CD11b/CD18 was purified from PMNs by LM2/1 immunoaffinity chromatography as described previously [3, 17] and immunoblotted using anti-Le x , anti-Le a ,
anti-CD18, and anti-CD11b mAbs.
PMN and intestinal epithelial cell immunostaining
Isolated PMNs were fixed with 3.7% paraformaldehyde and, where indicated, permeabilized with 0.5% Triton-X. After blocking with 3% BSA, PMNs were incubated with 10 mg/ml of the indicated Abs. After washing, PMNs were incubated with an FITC-labeled secondary Ab and mounted in ProLong antifading embedding solution (Thermo Fisher Scientific). Nuclei were visualized by staining with TO-PRO-1 (Thermo Fisher Scientific). Images shown are representative of PMN from $3 independent PMN donors with multiple images captured per donor. Immunofluorescent labeling of IECs was achieved as follows. T84 and Caco2 monolayers were fixed using methanol and, subsequently, blocked with 3% BSA. Monolayers were then incubated with primary Abs (10 mg/ml) and fluorescently labeled secondary Abs. After Ab incubations, IECs were mounted in ProLong antifading embedding solution. Images shown are representative of $3 experiments with multiple images taken per monolayer using a Leica Inverted SP5 Confocal Microscope System (Leica Biosystems, Bannockburn, IL, USA).
PMN transmigration assays
For transepithelial migration experiments, IECs were grown on collagencoated, permeable, 0.33-cm 2 , polycarbonate filters (5 mm pore size; CoStar Group, Washington DC, USA), as described previously [4, 14, 18] . All epithelial migration experiments were performed in the physiologically relevant basolateral-to-apical direction (i.e., inverted monolayers), in the presence of a chemotactic gradient of 100 nM fMLF. For migration experiments, 1 3 10 6 PMNs pretreated with 10 mg/ml of the indicated Abs, lectins, or soluble Lewis A trisaccharide were added to the upper chambers of transwell inserts and migration was measured at 37°C for 1 h. Transmigrated PMNs were quantified by assaying for the PMN azurophilic marker myeloperoxidase, as published previously [18] . Briefly, Triton X-100 was added to the lower reservoir of the transwell (final concentration 0.5%), and the pH was adjusted to 4.2 with citrate buffer. For each sample, color development was assayed at 405 nm on a microtiter plate reader after mixing equal parts of sample and a solution containing 1 mM 2,29-azino-di-(3-ethyl)dithiazoline sulfonic acid and 10 mM H 2 O 2 in 100 nM citrate buffer pH 4.2. The assay was standardized with known dilutions of the same PMNs used in each experiment and was linear in the range used (0.05 3 10 6 -1 3 10 6 PMNs). The percentage of migration represents the percentage of the 1 3 10 6 PMNs added (for each sample)
to the upper portion of the transwell system. For PMN chemotaxis assays, PMNs were incubated with 10 mg/ml of the indicated Abs, lectins, or soluble Lewis A trisaccharides before migration across collagen-coated, permeable, 0.33-cm 2 , polycarbonate filters to 100 nm fMLF, or 100 nM IL-8 was assessed by measurement myeloperoxidase, as described above. Data are means 6 SE (n = 5).
Flow cytometry and phagocytosis analyses
For flow cytometry analyses, nonstimulated PMNs or PMNs stimulated with 10 nM fMLF were blocked in 3% BSA with Human TruStain FcX (FC Receptor Blocking Solution; BioLegend, San Diego, CA, USA) before incubation with 10 mg/ml anti-Le a mAb, 10 mg/ml anti-CD11b mAb, 10 mg/ml anti-Le x mAb, or an IgG isotype-matched control mAb.
Following primary Ab incubation, PMNs were washed and incubated with relevant, fluorescently labeled, secondary mAbs and fixed in 3.7% paraformaldehyde, before analysis by flow cytometry. Flow cytometric analysis was carried out using a FACScan (Becton Dickinson, Franklin Lakes, NJ, USA), equipped with an argon ion laser tuned at a 488-nm wavelength. Data are representative of PMNs isolated from 3-5 healthy donors. For analysis of changes in surface expression of Le x and CD18/CD11b, PMNs were incubated with 10 mg/ml anti-Le a mAb (7LE), 10 mg/ml isotype matched control mAb, or 10 nm fMLF, before blocking in 3% BSA with Human TruStain FcX and subsequent incubation with 10 mg/ml FITC-labeled anti-Le x and FITC-labeled anti-CD11b mAbs. For phagocytosis assays, PMNs were incubated with 10 mg/ml relevant Abs and FITC-conjugated FluoSpheres (Thermo Fisher Scientific) at a ratio of 1:100 (PMN to FluoSpheres) in the presence of 10 nM fMLF, 10 mg/ml anti-Le a mAb (7LE), 10 mg/ml IgG isotypematched control mAb, or 10 mg/ml MBL for 30 min at 37°C. Uptake of FluoSpheres by PMNs was assessed by flow cytometry using an argon laser tuned at a 488-nm wavelength.
Transcriptional analysis
HL60 cells or human PMNs were lysed in TRIzol (Thermo Fisher Scientific) then subjected to phenol-chloroform extraction, according to the manufacturer's protocol [19] . RNA was digested with DNaseI (Ambion, Austin, TX, USA) to remove contamination with genomic DNA; then, DNA was synthesized by reverse transcription using oligo(dt12-18) primers and Superscript II reverse transcriptase (Thermo Fisher Scientific). Real-time PCR was performed with a MyIQ real-time PCR machine and SYBR Green supermix (Bio-Rad Laboratories, Hercules, CA, USA). Data were analyzed by the DDC t threshold cycle method and normalized to the housekeeping gene GAPDH. Data are means 6 SE from 5 healthy blood donors (n = 5).
Data analysis
Statistical differences were determined by 2-factor ANOVA using PRISM 5 for Mac OSX (version 5.0a 1992-1998; GraphPad Software, La Jolla, CA, USA).
Values are expressed as the means 6 SE from $3 separate experiments.
RESULTS
PMNs express the type 1 glycan Le a
Although it has been widely reported that PMNs express type 2 Lewis glycans, including Le x and sLe x , abundantly [6, 20] , and that these glycans regulate important functions, including migration, phagocytosis, and degranulation, it is not known whether PMNs express the type 1 Lewis glycan Le a (Fig. 1A) and what its function might be. Immunoblotting of lysates from human PMNs revealed expression of several large Le a glycans containing glycoproteins between 100 and 250 kDa (Fig. 1B) . To determine whether PMN-expressed Le a was displayed as part of larger N-or O-linked glycan structures, PMN lysates were treated with PNGaseF, an N-glycosidase that cleaves all types of asparagine-bound N-glycans. As shown in Fig. 1C Fig. 1E and F) . As a positive control for fMLF-mediated PMN activation, surface expression of the b2 integrin CD18/CD11b was also measured. In contrast to the unchanging expression of Le a , there was a significant increase in surface expression of CD18/CD11b after PMN activation with fMLF ( Fig. 1E and F [21, 22] , expression of Le a was also observed on circulating PMNs in noninflamed tissue as well as on infiltrating PMNs in the intestinal mucosa of individuals with ulcerative colitis (Fig. 1G) .
Binding specificity of anti-Le a mAb 7LE
To exclude the possibility of nonspecific binding of anti-Le a mAbs to the closely related PMN-expressed Lewis glycan stereoisomer Le x , glycan array analyses were performed. Such analyses afford identification of highly specific presentations of Le a glycans recognized by anti-Le a mAbs at a molecular/ structural level. The anti-Le a mAb 7LE was assayed for binding to a panel of 610 mammalian glycan structures using the version 5.1 glycan microarray from the CFG. Analyses revealed that 7LE bound with highest affinity to glycans expressing Galb1-3(Fuca1-4)GlcNAc (Le a ), in which the Le a structure was expressed in a terminal, nonreducing position (13,115 RFU, glycan 127; Fig. 2 ). The 7LE also recognized glycans containing terminal Le a determinants in repeating poly-Le a structures (2502 RFU, glycan 278). Importantly, there was no recognition by the anti-Le a mAb of the stereoisomer glycan structure Le x (glycan 152; Fig. 2 ). Further, 7LE showed no binding to glycans containing only an internal Le a sequence (glycans 395, 473, Supplemental Fig. 1 ). Interestingly, 7LE also failed to recognize glycans terminating with the sialylated version of Le a (sLe a ) (glycans 240, 331, 239). Taken together, these results highlight the highly restricted and (Fig. 3A) in ND vs. Dif HL60 cells. Interestingly, increased expression of the a1,4 fucosyltransferase FUT3 as well as the galactosyltransferase b3Galt1 was observed when HL60 cells were Dif toward a PMN-like state (Fig. 3B ). These differences in expression were further quantified by real-time PCR. Analyses revealed an 80-fold increase in the expression of FUT3 (***P , 0.001), a 90-fold increase in the expression of b3Galt1 (*** P , 0.001), and a 30-fold increase in the expression of b3Galt4 (*** P , 0.001) in Dif HL60 cells relative to ND HL60 cells (Fig. 3C) . Analysis of protein expression revealed a similar increase in the expression of FUT3 and b3Galt4 upon HL60 differentiation (Fig. 3D) . Analysis of gene expression in human PMNs confirmed expression of the a1,4 fucosyltransferase FUT3 as well as the galactosyltransferase b3Galt4 (Fig. 3E) . However, in contrast to Dif HL60 cells, no expression of b3Galt1 was observed in human PMNs (Fig. 3E) . The absence of contaminating eosinophils in PMN cDNA samples was confirmed by the lack of expression of the eosinophil marker MBP. Robust protein expression of both FUT3 and b3Galt4 was observed in PMNs from 5 healthy donors (Fig. 3F ). Fig. 4D ), suggesting that it is Le a expressed on PMN that is crucial for mediating the enhanced transepithelial migration. The effects of directly targeting PMN Le a on PMN trafficking were also studied in transmigration assays, where PMNs migrate across acellular, collagen-coated transwell filters. These data demonstrate that targeting of PMN-expressed Le a with 10 mg/ml anti-Le a mAbs (7LE and SPM522) and 10 mg/ml MBL results in enhanced transmigration across collagen to both fMLF and IL-8 (**P . 0.01, ***P . 0. 001, Fig. 4E and F). Specificity of Le a glycans in mediating observed increases in PMN migration was confirmed in transmigration experiments with PMN derived from human donors that lack Le a . Such individuals have a point mutation in FUT3, which results in its inability to fucosylate in the a1-4 position. As shown in Fig.4G , PMNs from a donor with a loss of function mutation in Fuc-T3 do not express Le a . In contrast, PMNs from the same donor express normal levels of Le x ( Fig. 4G and H) . In addition, treatment of PMN from a Le a -negative donor with anti-Le a mAbs or MBLs did not result in significantly increased PMN transmigration relative to PMN treated with J10.4, an IgG binding control mAb or control PMN not treated with any mAb (Fig. 4I) . Although targeting of Le a had no effect on PMN transmigration across collagen, treatment of PMNs deficient in a1-4 fucosylation with mAbs to Le x (which requires a1-3 and not a1-4 fucosylation for its synthesis) did result in a large decrease in PMN transmigration (Fig. 4I) as we have previously reported [6] . Taken together, these data highlight specific recognition of PMN-expressed Le a trisaccharide by anti-Le a mAbs and MBLs, as well as the functional effects of targeting Le a during PMN transmigration. -biding lectin MBL (10 mg/ml) increase PMN TEM to the chemoattractant fMLF (100 nM) across T84 IECs relative to IgG or lectin controls. Data shown are means 6 SE using PMNs from n = 5 independent donors. ***P , 0.001. (B) Immunoblot demonstrating expression of Le a in T84, but not Caco2, IECs. Data shown are representative of n = 3 Western blots. (C) Confluent T84 or Caco2 monolayers were costained with 10 mg/ml anti-ZO1 (green) or 10 mg/ml anti Le a mAb 7LE (red). Protein localization was determined by confocal microscopy analysis. Representative images from n = 3 experiments are shown both en face and in the x-z plane of the section. (D) Anti-Le a mAbs 7LE (10 mg/ml) and SPM522 (10 mg/ml) and the Le a -biding lectin MBL (10 mg/ml) increase PMN TEM to fMLF (100 nM) across Caco2 IECs. Data are means 6 SE from n = 3 blood donors. ***P , 0.001. Engagement of Le a increases PMN transmigration across collagen-coated transwells to fMLF (100 nM) (E) or IL-8 (100 nM) (F). Data are means 6 SE from n = 5 blood donors. ***P , 0.001; **P , 0.01. 
Selective targeting of Le a increases PMN migration
DISCUSSION
Although PMN migration into mucosal tissues is essential for effective host defense against invading pathogens, dysregulated PMN migration is implicated in the pathology of many chronic inflammatory conditions, including rheumatoid arthritis, myocardial reperfusion injury, chronic obstructive pulmonary disease, and inflammatory bowel disease [24] [25] [26] [27] [28] . Recent evidence has shown that migration of PMNs into epithelial-lined organs, such as the intestine, is, in part, regulated through glycanmediated adhesion events. For example, we have demonstrated that mAb targeting of sLe a on the epithelial protein CD44v6 blocks PMN TEM into the intestinal lumen [4, 5] and that targeting of the related PMN-expressed Lewis glycan Le x also blocks PMN TEM [6] . Blood group Ags, including ABH Ags and Le a /Le b , represent glycan residues attached at the nonreducing ends of glycoconjugates, which have fundamental roles in mammalian cell-to-cell communications at sites of inflammation [7] [8] [9] [10] [11] . Although it has been previously demonstrated that human PMNs express type 2 Lewis glycans (Le x and sLe x ) [3, 20, 29] , it has also been previously reported that PMNs do not express the related Lewis glycans sLe a [5] and Le b [6] . Additionally, it has been reported that Le a is expressed by inflamed and noninflamed intestinal epithelium [21, 22] . However, to date, there have been no studies, to our knowledge, looking at expression of Le a by PMNs. Given the important role of Le x , sLe x , and sLe a in regulating PMN trafficking, we examined expression of Le a in human PMNs and demonstrated expression of several Le a -containing, N-linked glycoproteins. Consistent with that, generation of N-glycan-linked Le a has been reported previously in other cell types [30, 31] . In addition to PMN-expressed Le a , expression of Le a in noninflamed and inflamed mucosal epithelial tissue, as well as in T84 model IECs, was observed in the current study. Consistent with these data, there is a report of Le a expression in the mucosa from individuals with ulcerative colitis that compared the extent of epithelial Le a staining between inflammatory lesions and adjacent noninflammatory mucosal regions [21, 22] . Although the purpose of these studies was to evaluate differences in [32, 33] . The Le a -Le a binding protein MBL is also known to have a role in innate immunity through activation of complement in addition to functioning as an opsonin through direct binding of pathogen glycans [34] . Finally, array analysis also revealed that there was no recognition of glycan structures containing only internal Le a structures by 7LE, once again highlighting the importance of the specific affinity of GBPs for terminally expressed glycan residues.
Glycan recognition by GBPs (including mAbs and lectins) is accomplished through interactions between protein amino acid side chains and multiple chemical moieties, including hydroxyl groups, N acetyl groups, and carboxylic acids on glycans. The chemical nature and stereochemical placement of each moiety can drive GBP-mediated recognition, such that even small differences at an atomic level are often important for binding interactions. In keeping with the latter, there was no recognition by the anti-Le a mAb 7LE of glycan structures very similar to Le a , including sLe a and Le x present on the version 5.1 glycan array. In addition, 7LE failed to recognize sulfated Le a glycans present on the array. Interestingly, sLe a glycans can act as potent ligands for E-selectin [35] .
The biosynthesis of terminal glycan structures including Lewis glycans proceeds from precursors by stepwise addition of monosaccharide units through the actions of discrete glycosyltransferases. From the type 1 chain the biosynthesis of Le a proceeds through the activities of a b3GalT and a1,4 FucT [23] . In support of Le a biosynthesis by PMN, we show that when HL60 myelomonocytic cells are differentiated toward a PMNlike state there is a marked increase in the expression of b3Galt1, bGalt4 and FUT3. HL60 cells induced to differentiate with DMSO have many of the functional characteristics of circulating peripheral blood granulocytes such as phagocytosis, complement receptor activity, chemotaxis and the ability to reduce NBT. However, it has also been reported that differentiated HL60 cells retain surface glycan features characteristic of immature undifferentiated cells [36, 37] . Given this, expression of glycosyltransferases was also examined in isolated human PMN where robust RNA and protein expression of both b3Galt4 and FUT3 was observed. Further, the lack of expression of b3Galt1 observed in PMN is consistent with previous studies reporting that differentiated HL60 cells express glycosyltransferases that are not found in mature circulating PMN [36] .
Given the importance of glycan-mediated binding interactions during PMN trafficking [5, 6] [6] . Analysis of CD18/CD11b (purified from human PMN by LM2/1 immunoaffinity) by immunoblotting revealed 2 protein bands recognized by anti-CD18 and anti-CD11b mAbs (Supplemental Fig. 2A) [6] , whereas ligation of Le a had no effect on other PMN functions (Supplemental Fig. 2B and C) . Our studies also demonstrated that epithelial-expressed Le a is not required for an enhanced migratory response because PMN TEM across Caco2 IECs (which do not express Le a ) was also increased downstream of engagement of PMN-expressed Le a . This lack of expression of Le a by Caco2 is consistent with a previous report showing no expression of FUT3 in these IECs [5] . Consistent with the role of PMN-expressed Le a mediating increased PMN trafficking, engagement of PMN Le a also resulted in increased PMN trafficking across collagen-coated support filters, an effect that was lost using PMN from a Le a -deficient individual. Because FUT3 encodes the a1-3/4 fucosyltransferase required to synthesize Le a , homozygotic carriers of 1 of several point mutations that inactivate FUT3 lack Le a Ags and, as such, are denoted as Lewis-negative individuals (constituting about 5% of the white population) [38, 39] . Consistent with specific mAb/ MBL targeting of PMN Le a mediating functional effects observed during PMN TEM, treatment of PMN from an individual incapable of a1-4 fucosylation (that do not express Le a on their surface) with anti-Le a mAbs/Le a binding lectin did not result in significantly increased PMN transmigration. Highlighting the relevance of glycans to mucosal inflammation, it has been previously reported that frequencies of FUT3 polymorphisms are higher in patients with ulcerative colitis than in healthy controls. Furthermore, stratified analyses indicate that mutant alleles of FUT3 are more common in patients with distal colitis than in those with more extensive colitis [21] . In addition, although the precise etiology of inflammatory bowel disease is not yet fully understood, abnormal host-microbial interactions have been implicated in disease pathogenesis. Interestingly, it has been reported that terminal Lewis Ags (including Le a ) can act as binding sites for invading microbes, including Helicobacter pylori, Campylobacter jejuni, norovirus, and rotavirus [40] [41] [42] . Indeed, reports have already shown that Le a -negative individuals lack attachment factors for most norovirus strains and are thus less prone to norovirus infection [43, 44] . Therefore, the expression of Le a on human PMNs could have important implications for host immune responses beyond PMN trafficking during intestinal inflammation. Deeper understanding of the interactions between specific glycans (including Le a ) and GBPs will likely lead to new insights into, and understanding of, human disease and, thus, has great potential to uncover novel mechanism-based antiinflammatory therapeutics.
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